Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines

Cancer Research
Katarzyna JastrzebskiLodewyk F A Wessels

Abstract

Cancer cell lines differ greatly in their sensitivity to anticancer drugs as a result of different oncogenic drivers and drug resistance mechanisms operating in each cell line. Although many of these mechanisms have been discovered, it remains a challenge to understand how they interact to render an individual cell line sensitive or resistant to a particular drug. To better understand this variability, we profiled a panel of 30 breast cancer cell lines in the absence of drugs for their mutations, copy number aberrations, mRNA, protein expression and protein phosphorylation, and for response to seven different kinase inhibitors. We then constructed a knowledge-based, Bayesian computational model that integrates these data types and estimates the relative contribution of various drug sensitivity mechanisms. The resulting model of regulatory signaling explained the majority of the variability observed in drug response. The model also identified cell lines with an unexplained response, and for these we searched for novel explanatory factors. Among others, we found that 4E-BP1 protein expression, and not just the extent of phosphorylation, was a determinant of mTOR inhibitor sensitivity. We validated this finding experimentally and ...Continue Reading

Associated Datasets

Jan 9, 2019·Bram Thijssen, Katarzyna Jastrzebski

References

Aug 1, 1993·Genes, Chromosomes & Cancer·C TheilletP Gaudray
Apr 28, 2000·The International Journal of Biochemistry & Cell Biology·M E MartínJ L Fando
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Dec 29, 2005·Molecular Cancer Research : MCR·Véronique Gelsi-BoyerMax Chaffanet
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Oct 29, 2008·Proceedings of the National Academy of Sciences of the United States of America·Andrew Y ChooJohn Blenis
Aug 31, 2011·Proceedings of the National Academy of Sciences of the United States of America·Nina IlicThomas M Roberts
Oct 18, 2011·Proceedings of the National Academy of Sciences of the United States of America·Laura M HeiserPaul T Spellman
Jan 10, 2012·BMC Systems Biology·Bettina M LängerNéstor V Torres
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 27, 2012·Cancer Research·Tommy AlainNahum Sonenberg
Jun 12, 2013·Molecular Systems Biology·Bertram KlingerNils Blüthgen
Nov 2, 2013·Genome Biology·Anneleen DaemenJoe W Gray
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jun 10, 2014·Molecular Oncology·Floris H Groenendijk, René Bernards
Jan 17, 2015·Cancer Research·Jerry PelletierNahum Sonenberg
Mar 7, 2015·Nature Reviews. Drug Discovery·Mamatha BhatIvan Topisirovic
Oct 21, 2015·Cancer Discovery·Brinton Seashore-LudlowStuart L Schreiber
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N HortobagyiJosé Baselga
Jul 12, 2016·Cell·Francesco IorioMathew J Garnett
Oct 23, 2016·BMC Systems Biology·Bram ThijssenLodewyk F A Wessels

❮ Previous
Next ❯

Citations

May 19, 2019·Breast Cancer Research : BCR·Veronika RamovsArnoud Sonnenberg
Nov 14, 2018·Bioinformatics·Evert BosdrieszLodewyk F A Wessels

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.